<SEC-DOCUMENT>0001140361-22-025709.txt : 20220711
<SEC-HEADER>0001140361-22-025709.hdr.sgml : 20220711
<ACCEPTANCE-DATETIME>20220711160543
ACCESSION NUMBER:		0001140361-22-025709
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20220711
FILED AS OF DATE:		20220711
DATE AS OF CHANGE:		20220711

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Immunocore Holdings plc
		CENTRAL INDEX KEY:			0001671927
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39992
		FILM NUMBER:		221077012

	BUSINESS ADDRESS:	
		STREET 1:		90 PARK DRIVE
		STREET 2:		MILTON PARK, ABINGDON
		CITY:			OXFORDSHIRE
		STATE:			X0
		ZIP:			OX14 4RY
		BUSINESS PHONE:		01235 5430281

	MAIL ADDRESS:	
		STREET 1:		90 PARK DRIVE
		STREET 2:		MILTON PARK, ABINGDON
		CITY:			OXFORDSHIRE
		STATE:			X0
		ZIP:			OX14 4RY

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Immunocore Ltd
		DATE OF NAME CHANGE:	20160412
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>brhc10039545_6k.htm
<DESCRIPTION>6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using EDGARfilings PROfile 8.4.0.0
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div>
      <div style="text-align: center; font-size: 14pt; font-weight: bold;">UNITED STATES</div>
      <div style="text-align: center; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
      <div style="text-align: center; font-size: 12pt; font-weight: bold;">Washington, D.C. 20549</div>
      <div><br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 25%; color: #000000; text-align: center;"></div>
      <div style="font-weight: 400;"> <br>
      </div>
      <div style="text-align: center; font-size: 18pt; font-weight: bold;">FORM 6-K</div>
      <div>&#160;</div>
      <div>
        <hr noshade="noshade" align="center" style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 25%; color: #000000; text-align: center;"></div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">REPORT OF FOREIGN PRIVATE ISSUER</div>
      <div style="text-align: center; font-weight: bold;">PURSUANT TO RULE 13a-16 OR 15d-16</div>
      <div style="text-align: center; font-weight: bold;">UNDER THE SECURITIES EXCHANGE ACT OF 1934</div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">For the Month of July 2022</div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">Commission File Number: 001-39992</div>
      <div style="text-align: center; font-weight: bold;"> <br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 25%; color: #000000; text-align: center;"></div>
      <div style="font-weight: 400;"> <br>
      </div>
      <div style="text-align: center; font-size: 24pt; font-weight: bold;">Immunocore Holdings plc</div>
      <div style="text-align: center; font-weight: bold;">(Translation of registrant&#8217;s name into English)</div>
      <div style="font-weight: 400;"> <br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 25%; color: #000000; text-align: center;"></div>
      <div style="font-weight: 400;"> <br>
      </div>
      <div style="text-align: center; font-weight: bold;">92 Park Drive</div>
      <div style="text-align: center; font-weight: bold;">Milton Park</div>
      <div style="text-align: center; font-weight: bold;">Abingdon, Oxfordshire OX14 4RY</div>
      <div style="text-align: center; font-weight: bold;">United Kingdom</div>
      <div style="text-align: center; font-weight: bold;">&#160;(Address of principal executive office)</div>
      <div style="text-align: center; font-size: 8pt; font-weight: bold;"> <font style="font-size: 10pt;"><br>
        </font></div>
      <div>
        <hr noshade="noshade" align="center" style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 25%; color: #000000; text-align: center;"></div>
      <div>&#160;</div>
      <div>Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:</div>
      <div>&#9746;&#160; Form 20-F&#160; &#160; &#9744;&#160; Form 40-F</div>
      <div>&#160;</div>
      <div>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): &#9744;</div>
      <div>&#160;</div>
      <div>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&#160; &#9744;</div>
      <div> <br>
      </div>
      <div>
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"> </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: center; font-weight: bold;">INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K</div>
      <div>&#160;</div>
      <div style="text-align: justify; font-weight: bold;">Press Release</div>
      <div>&#160;</div>
      <div style="text-align: justify;">On July 11, 2022, Immunocore Holdings plc (the &#8220;Company&#8221;) announced the dosing of the first patient in its first-in-human Phase 1 clinical trial of IMC-M113V, a new class of bispecific protein immunotherapy that is
        being developed for the treatment of patients with human immunodeficiency virus infection. A copy of this press release is furnished as Exhibit 99.1 to this Report on Form 6-K.</div>
      <div>&#160;</div>
      <div style="text-align: justify;">This Report on Form 6-K, including Exhibit 99.1 hereto, shall be deemed to be incorporated by reference into the Company&#8217;s registration statement on Form F-3ASR (File No. 333-264105) and the Company&#8217;s registration
        statements on Form S-8 (File Nos. 333-226457 and 333-265000) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.</div>
      <div style="text-align: justify;"> <br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: center; font-weight: bold;">EXHIBIT INDEX</div>
      <div style="text-align: center; font-weight: bold;"> <br>
      </div>
      <div style="text-align: center; font-weight: bold;">
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="zb6cb4967c50f4b149c793640a02c3b15">

            <tr>
              <td style="width: 8%; border-bottom: 2px solid rgb(0, 0, 0);">
                <div>
                  <div style="text-align: center; font-weight: bold;">Exhibit</div>
                  <div style="text-align: center; font-weight: bold;">No.</div>
                </div>
              </td>
              <td style="width: 2%; padding-bottom: 2px;" colspan="1">&#160;</td>
              <td style="width: 90%; border-bottom: 2px solid rgb(0, 0, 0); text-align: center; vertical-align: bottom;">
                <div>&#160;<font style="font-weight: bold;">Description</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 8%;">
                <div><a href="brhc10039545_ex99-1.htm"><font style="color: rgb(0, 0, 0);">99.1</font></a></div>
              </td>
              <td style="width: 2%;" colspan="1">&#160;</td>
              <td style="width: 90%;">
                <div>&#160;Press Release dated July 11, 2022.</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="text-align: center; font-weight: bold;"> <br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: center; font-weight: bold;">SIGNATURES</div>
      <div>&#160;</div>
      <div>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</div>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" id="zcb6b1c5ebbd74b70a6175de7b79afbd0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 45%; vertical-align: top;">&#160;</td>
            <td style="vertical-align: top;" colspan="3">
              <div style="font-weight: bold;">IMMUNOCORE HOLDINGS <font style="color: rgb(0, 0, 0);">PLC</font></div>
            </td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: middle;">&#160;</td>
            <td style="width: 45%; vertical-align: middle;">&#160;</td>
            <td style="width: 3%; vertical-align: bottom;">&#160;</td>
            <td style="vertical-align: bottom;" colspan="2">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
              <div style="color: rgb(0, 0, 0);">Date:</div>
            </td>
            <td style="width: 45%; vertical-align: bottom; padding-bottom: 2px;">
              <div style="color: rgb(0, 0, 0);">July 11, 2022</div>
            </td>
            <td style="width: 3%; vertical-align: top; padding-bottom: 2px;">
              <div style="color: rgb(0, 0, 0);">By:</div>
            </td>
            <td style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
              <div>/s/ <font style="color: rgb(0, 0, 0);">Bahija Jallal, Ph.D.</font></div>
            </td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 45%; vertical-align: top;">&#160;</td>
            <td style="width: 3%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Name:</div>
            </td>
            <td style="width: 42%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Bahija Jallal, Ph.D.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 45%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 3%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 5%; vertical-align: top;" rowspan="1">Title:</td>
            <td style="width: 42%; vertical-align: top;" rowspan="1">&#160;Chief Executive Officer</td>
          </tr>

      </table>
      <div>&#160;</div>
      <div><br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>brhc10039545_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using EDGARfilings PROfile 8.4.0.0
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div style="text-align: right;"><font style="font-weight: bold;">Exhibit 99.1</font><br>
    </div>
    <div> <br>
    </div>
    <div style="text-align: right;"> <img src="logo1.jpg">
      <div><br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    </div>
    <div> <br>
    </div>
    <div>
      <div style="color: #0A414E; font-family: 'Times New Roman', Times, serif; font-style: italic; font-weight: bold;">PRESS RELEASE</div>
      <div><br>
      </div>
      <div style="text-align: center; color: #09476E; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Immunocore announces dosing of first patient with ImmTAV&#174; bispecific for HIV</div>
      <div><br>
      </div>
      <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-style: italic;">IMC-M113V, T cell receptor bispecific, targets an HIV Gag antigen</div>
      <div><br>
      </div>
      <div style="text-align: center; font-family: 'Times New Roman', Times, serif;"><font style="font-style: italic;">Single Ascending Dose portion of Phase 1 study to
          evaluate safety,</font>&#160;<font style="font-style: italic;">antiviral activity, and pharmacokinetics</font></div>
      <div><br>
      </div>
      <div>
        <div style="text-align: justify; font-family: 'Times New Roman', Times, serif;">(OXFORDSHIRE, England &amp; CONSHOHOCKEN, Penn. &amp; ROCKVILLE, Md., US, 11 July 2022) Immunocore Holdings plc (Nasdaq: IMCR) (&#8220;Immunocore&#8221; or the
          &#8220;Company&#8221;), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, autoimmune and infectious
          diseases, today announces the dosing of the first patient in the first-in-human Phase 1 clinical trial of IMC-M113V, a new class of bispecific protein immunotherapy that is being developed for the treatment of patients with human immunodeficiency
          virus (HIV) infection.</div>
        <div><br>
        </div>
        <div style="text-align: justify; font-family: 'Times New Roman', Times, serif;">IMC-M113V is the second candidate in development using Immunocore&#8217;s immune&#8208;mobilising monoclonal T cell receptors against virus (ImmTAV&#174;) platform to
          enter clinical trials. IMC-M113V is an immunotherapeutic approach designed to specifically eliminate CD4+ cells that are persistently infected with HIV (&#8216;reservoirs&#8217;). IMC-M113V targets a peptide derived from the Gag protein that is presented by
          HLA*A02 on the surface of HIV infected cells. Reduction in the number of these cells is one way to potentially achieve a state of viral suppression in the absence of anti-retroviral medications, or a &#8216;functional cure.&#8217;</div>
        <div><br>
        </div>
        <div style="text-align: justify; font-family: 'Times New Roman', Times, serif;">There are currently over 30 antiretroviral medications spanning six drug classes approved for the treatment of HIV. If started early, antiretroviral
          therapy (ART) provides people with HIV with a normal life expectancy, prevents immunodeficiency and stops the spread of the virus. However, this treatment does not &#8216;cure&#8217; the disease and must be continued for life to prevent relapse.</div>
        <div><br>
        </div>
        <div style="text-align: justify; font-family: 'Times New Roman', Times, serif;">&#8220;HIV remains a major global public health challenge with the need for a functional cure&#8221; <font style="font-weight: bold;">said Lucy Dorrell MD, Head of Infectious Diseases at Immunocore</font>. &#8220;IMC-M113V is the first soluble TCR bispecific targeting HIV to enter the clinic. We hope that the start of this study is the next step to
          potentially bring a transformative treatment to millions of HIV infected people around the world.&#8221;</div>
        <div><br>
        </div>
        <div style="text-align: justify; font-family: 'Times New Roman', Times, serif;">As part of the<font style="color: #000000;"> collaboration agreement between Immunocore
            and the Bill and Melinda Gates Foundation, Immunocore and the Gates Foundation are committed to working together for HIV product candidate development and ensuring that any resulting HIV product that receives necessary regulatory approval is
            made available to people in developing countries at an affordable price.</font></div>
        <div><br>
        </div>
        <div style="text-align: justify; font-family: 'Times New Roman', Times, serif;"><font style="font-weight: bold;">Professor Sarah Fidler, PhD, Imperial College of London
            Department of Infectious Disease</font>&#160;<font style="font-weight: bold;">commented</font>: &#8220;There are nearly 38 million people around the world living with HIV and despite the
          accessibility of anti-retroviral therapy (ART), this is still a significant unmet need. The potential for a TCR therapy for HIV would be a ground-breaking development which would remove the need for patients to continuously take ART- for the
          remainder of their lives, providing significant relief to one of the world&#8217;s largest public health issues.&#8221;</div>
        <div><br>
        </div>
        <div>
          <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
        <div><br>
        </div>
      </div>
      <div style="text-align: right; color: #09476E; font-family: 'Times New Roman', Times, serif;">Immunocore Holdings plc, 92 Park Drive, Milton Park, Abingdon, Oxon, OX14 4RY, UK</div>
      <div style="text-align: right; color: #09476E; font-family: 'Times New Roman', Times, serif;">T: +44 (0)1235 438600 | www.immunocore.com</div>
      <div style="text-align: right; color: #09476E; font-family: 'Times New Roman', Times, serif;">Registered in England no: 6456207 | VAT No. GB 939 6694 55</div>
      <div style="font-family: 'Times New Roman', Times, serif;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageFooter"></div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
        <div id="DSPFPageHeader"></div>
      </div>
      <div><br>
      </div>
      <div>
        <div style="text-align: justify; font-family: 'Times New Roman', Times, serif;">The trial is an ongoing open label study evaluating the safety, antiviral activity, and pharmacokinetics of IMC-M113V in HLA-A*02:01 positive patients
          with HIV who are currently receiving standard of care anti-retroviral therapy.</div>
        <div><br>
        </div>
        <div style="text-align: justify; font-family: 'Times New Roman', Times, serif;">&#160;###</div>
        <div><br>
        </div>
        <div style="text-align: justify; color: #000000; font-family: 'Times New Roman', Times, serif; font-weight: bold;">About ImmTAV molecules and infectious diseases</div>
        <div style="text-align: justify; color: #000000; font-family: 'Times New Roman', Times, serif;">ImmTAV (Immune mobilising monoclonal TCRs Against Virus) molecules are novel bispecific molecules that, like ImmTAC (Immune mobilising
          monoclonal TCRs Against Cancer) molecules, are designed to enable the immune system to recognize and eliminate virally infected cells.</div>
        <div><br>
        </div>
        <div style="text-align: justify; color: #000000; font-family: 'Times New Roman', Times, serif;">Immunocore is advancing clinical candidates to cure patients with HIV and hepatitis B virus (HBV). The Company aims to achieve
          sustained control of HIV after patients stop ART, without the risk of virological relapse or onward transmission. This is known as &#8216;functional cure&#8217;. For the treatment of HBV, the Company aims to achieve sustained loss of circulating viral
          antigens and markers of viral replication after stopping medication for people living with chronic HBV.</div>
      </div>
      <div><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-weight: bold;">About Immunocore</div>
      <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called
        ImmTAX &#8211; Immune mobilizing monoclonal TCRs Against X disease &#8211; designed to treat a broad range of diseases, including cancer, autoimmune, and infectious disease. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is
        developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. Immunocore&#8217;s most
        advanced oncology TCR therapeutic, KIMMTRAK (tebentafusp-tebn), has been approved by the U.S. FDA for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma (mUM) having demonstrated an overall survival
        benefit in a randomized Phase 3 clinical trial in metastatic uveal melanoma, a cancer that has historically proven to be insensitive to other immunotherapies.</div>
      <div>
        <div><br>
        </div>
      </div>
      <div style="color: rgb(9, 71, 110); font-family: 'Times New Roman',Times,serif; font-size: 8pt; font-weight: bold;">Page 2 of 3</div>
      <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-weight: bold;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageFooter"></div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
        <div id="DSPFPageHeader"></div>
      </div>
      <div><br>
      </div>
      <div>
        <div style="text-align: justify; color: #000000; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Forward Looking Statements</div>
      </div>
      <div style="text-align: justify; color: #000000; font-family: 'Times New Roman', Times, serif;">This press release contains &#8220;forward-looking statements&#8221; within the meaning of the safe harbor provisions of the Private Securities
        Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release are forward-looking statements. These statements include, but are not limited to, statements regarding: the success of
        Company&#8217;s collaboration with the Gates Foundation; statements regarding clinical data from the ongoing trial of IMC-M113V; the ability of IMC-M113V to be an effective or transformative treatment for patients with HIV infection; the expected
        clinical benefits of IMC-M113V including its potential as a &#8220;functional cure&#8221;; and the Company&#8217;s plan for future development of IMC-M113V. Any forward-looking statements are based on management&#8217;s current expectations of future events and are
        subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, many of which are beyond the Company&#8217;s control. These risks and
        uncertainties include, but are not limited to, the impact of the ongoing COVID-19 pandemic and the Omicron variant on the Company&#8217;s business, strategy clinical trials and financial position; results from earlier pre-clinical studies of Immunocore&#8217;s
        product candidates including IMC-M113V may not necessarily be predictive of the results from required later pre-clinical studies and future clinical trials; actions of regulatory agencies, which may affect the initiation, timing and progress of
        clinical trials of IMC-M113V or future regulatory approval; Immunocore&#8217;s ability to obtain, maintain and enforce intellectual property protection; unexpected safety or efficacy data observed during preclinical studies or clinical trials; clinical
        trial site activation or enrolment rates that are lower than expected; changes in expected or existing competition; and the success of Immunocore&#8217;s current and future collaborations, partnerships or licensing arrangements including its
        collaboration with the Gates Foundation. These and other risks and uncertainties are described in greater detail in the section titled "Risk Factors" in Immunocore&#8217;s filings with the Securities and Exchange Commission, including Immunocore&#8217;s most
        recent Annual Report on Form 20-F for the year ended December 31, 2021 filed with the Securities and Exchange Commission on March 3, 2022, as well as discussions of potential risks, uncertainties, and other important factors in the Company&#8217;s
        subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information, except as required by law.</div>
      <div><br>
      </div>
      <div>
        <div style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">CONTACT:</div>
        <div><br>
        </div>
      </div>
      <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Immunocore</div>
      <div style="color: #000000; font-family: 'Times New Roman', Times, serif;">Debra Nielsen, Head of Communications</div>
      <div style="font-family: 'Times New Roman', Times, serif;">T: +1 (610) 368-8602</div>
      <div style="font-family: 'Times New Roman', Times, serif;">E: debra.nielsen@immunocore.com</div>
      <div style="font-family: 'Times New Roman', Times, serif;">Follow on Twitter: @Immunocore</div>
      <div><br>
      </div>
      <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Consilium Strategic Communications (corporate and financial)</div>
      <div style="color: #000000; font-family: 'Times New Roman', Times, serif;">Mary-Jane Elliott/ Chris Welsh/Jessica Hodgson</div>
      <div style="font-family: 'Times New Roman', Times, serif;">T: +44 (0)203 709 5700</div>
      <div style="color: #000000; font-family: 'Times New Roman', Times, serif;">E: <u>Immunocore@consilium-comms.com</u></div>
      <div><br>
      </div>
      <div style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">Investor Relations</div>
      <div style="font-family: 'Times New Roman', Times, serif;">Clayton Robertson, Head of Investor Relations</div>
      <div style="font-family: 'Times New Roman', Times, serif;">T: +1 215-384-4781</div>
      <div style="font-family: 'Times New Roman', Times, serif;">E: ir@immunocore.com</div>
      <div>
        <div><br>
        </div>
      </div>
      <div style="color: rgb(9, 71, 110); font-family: 'Times New Roman',Times,serif; font-size: 8pt; font-weight: bold;">Page 3 of 3</div>
      <div style="color: rgb(9, 71, 110); font-family: 'Times New Roman',Times,serif; font-size: 8pt; font-weight: bold;"> <br>
      </div>
      <div style="color: rgb(9, 71, 110); font-family: 'Times New Roman',Times,serif; font-size: 8pt; font-weight: bold;"> <br>
      </div>
      <div style="color: rgb(9, 71, 110); font-family: 'Times New Roman',Times,serif; font-size: 8pt; font-weight: bold;">
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo1.jpg
<TEXT>
begin 644 logo1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1"  > /@# 2(  A$! Q$!_\0
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M]K>5M7Y&^/S>53"_[)I-IM_W4M[^=]%YGZ>>(?VI-9TC_@G)-\8TL--;7H_
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M>Z1X4U*T:18M2>WGDB^SS;V($SJH92I 8Y7&<9_0C.17XV?LF_L"Z/\ M_\
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M!JO^PO\ L<^'?V%OV;M ^'_AY4E^P1^=J5_LVR:I>/@S3OW^9N ,\*%':O8
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M;^,OC%X5@O\ 2]?\<V7V/4M/CD0::&,B2/-'&$W*[L@+?-MR2<#->F?&_P"
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M,MK^TM;ZW/PQF8Q7$*RH2))L'# BOOH?"3PIC_D6/#W_ (+8?_B:^;_VRO\
M@D!X#_;5^.]K\1-:\6?$+PUXAL]+328W\/:E%9@0JSMU,3-DESGYL<#BO-_^
M(?7P'_T6+]H#_P *I/\ XS6U2>&K0I\U1Q<8I6Y;]_,PI4\50J5>6DI*4FT^
M9+>WD?=VCZ#8^'+/[/I]G:6%ODMY5O"L29/4X4 9HKP3]B3_ ()R^'_V&M9U
M^]T7QK\1?%;^((8H)4\3:L+Y+<1LS Q@(NTG=SUZ"BO*K1@IM4Y<R[VL>S0E
,-P3J1Y7VO?\ $__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
